Ribociclib in Combination With Non-steroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer

Sponsor
Novartis Pharmaceuticals
Study ID
NCT05569187
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • Ribociclib — DRUG
    Included patients who received doses (600 mg, 400 mg, and 200 mg) at 6 months and 1 year

Study Details

Observational, longitudinal (retrospective cohort), multicenter, national study aiming to evaluate the proportion of women with HR+/HER2- advanced breast cancer treated with ribociclib plus non-steroidal aromatase inhibitors who were alive and without disease progression at 1 year.

Key Dates

First listed
Oct 6, 2022
Start date
Mar 23, 2021
Status verified
Nov 2022
Primary completion
Oct 29, 2021
Completion
Oct 29, 2021

Study Design

Enrollment
76 participants (actual)

Arms

  • Arm: Ribociclib in combination with non-steroidal aromatase inhibitors
    Included patients who received doses (600 mg, 400 mg, and 200 mg) at 6 months and 1 year

Primary Outcome Measure

Proportion of patients alive and progression-free from disease at 1 year [ Time Frame: 1 year post-treatment ]

Find similar trials

Nationwide
Breast cancer trialsOncology trialsBreast oncology trialsWomen's health trials

Related Studies